Found 96 articles for: "oral contraceptive"
Efficacy, Safety, Satisfaction, Adherence to Treatment With Nano-Formulated Cysteamine Tranexamic Acid Cream to Treat Melasma
July 2024 | Volume 23 | Issue 7 | Original Article | 529 | Copyright © July 2024
Background: Melasma is a chronic pigmentary disorder. In this study, an innovative cream combining cysteamine and tranexamic acid (TXA) was assessed.Objectiv...
Read MoreSteroids Used to Treat Acne Vulgaris: A Review of Efficacy, Safety, and Clinical Considerations
June 2024 | Volume 23 | Issue 6 | Original Article | 404 | Copyright © June 2024
Acne vulgaris is prevalent among adolescents and adults worldwide and can significantly impact patients' quality of life. Steroidal molecules, including oral and intralesional corticosteroids, co...
Read MoreTreatments for Moderate-to-Severe Acne Vulgaris: A Systematic Review and Network Meta-analysis
April 2024 | Volume 23 | Issue 4 | Original Article | 216 | Copyright © April 2024
Background: Multiple treatment options exist for the management of moderate-to-severe acne. However, the comparative effectiveness (efficacy/safety) of moderate-to-severe acne tr...
Read MoreA Novel Systems-Wide Approach in Addressing Acne with a Multi-Targeting Nutraceutical
March 2024 | Volume 23 | Issue 3 | Original Article | 160 | Copyright © March 2024
Acne vulgaris (AV) is one of the top concerns dermatologists encounter from women. Until now, therapies addressing AV have largely centered around, and have been successful at, targeting the path...
Read MoreCysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action
February 2024 | Volume 23 | Issue 2 | Original Article | 9 | Copyright © February 2024
Background: Modified Kligman's formula (mKF) is the gold standard treatment for melasma; however, its prolonged use is not recommended due to side effects. Cysteamine is a potent...
Read MoreComparing the Efficacy and Tolerability of Moderate to Severe Hyperpigmentation and Skin Unevenness
January 2024 | Volume 23 | Issue 1 | Original Article | 1260 | Copyright © January 2024
Dyschromia is the result of irregular facial pigmentation. These cutaneous manifestations can have a significant impact on the quality of life of those affected, especially among females and skin...
Read MoreIntegrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris
January 2024 | Volume 23 | Issue 1 | Original Article | 1278 | Copyright © January 2024
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged 12 years or older based on results from two identical pivotal Phase 3 trials. In...
Read MoreLong-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris
August 2023 | Volume 22 | Issue 8 | Original Article | 810 | Copyright © August 2023
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged ≥ 12 years based on results from two 12-week Phase 3 studies in patients with...
Read MoreHormonal Treatments in Hidradenitis Suppurativa: A Systematic Review
August 2023 | Volume 22 | Issue 8 | Original Article | 785 | Copyright © August 2023
Background: Hidradenitis suppurativa (HS) is an inflammatory skin condition characterized by recurrent abscesses, nodules, and sinus tracts. Hormones are thought to play an impor...
Read MoreIndividual Article: Clascoterone Cream 1%: Mechanism of Action, Efficacy, and Safety of a Novel, First-in-Class Topical Antiandrogen Therapy for Acne
June 2023 | Volume 22 | Issue 6 | Supplement Individual Articles | SF350992s7 | Copyright © June 2023
Acne is a prevalent chronic inflammatory disease that can cause severe psychiatric effects and physical scarring of the skin. Historically, although systemic antiandrogen acne medications have be...
Read MoreThe Many Faces of Pediatric Acne: A Practical Algorithm for Treatment, Maintenance Therapy, and Skincare Recommendations for Pediatric Acne Patients
June 2023 | Volume 22 | Issue 6 | Original Article | 539 | Copyright © June 2023
Background: Pediatric acne is a common, complex, multifactorial inflammatory skin disease with various expressions in childhood that can be categorized by age, severity, and pube...
Read MoreUnmet Needs in the Management of Acne Vulgaris: A Consensus Statement
June 2023 | Volume 22 | Issue 6 | Original Article | 582 | Copyright © June 2023
Acne vulgaris is the most common skin condition in the US, affecting up to 50 million Americans. The American Academy of Dermatology (AAD) guidelines on acne treatment were developed to provide r...
Read MoreOptimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus
April 2023 | Volume 22 | Issue 4 | Original Article | 386 | Copyright © April 2023
Because of its complex pathogenesis, chronicity, and high rates of recurrence, melasma is regarded as a challenging skin disorder. Topical treatments are often offered as first-line therapy. Howe...
Read MoreUpdate on Hormonal Therapy in Hidradenitis Suppurativa
April 2023 | Volume 22 | Issue 4 | Original Article | 369 | Copyright © April 2023
Hidradenitis suppurativa (HS), a chronic inflammatory disorder of the apocrine-bearing skin, presents with deep seated inflamed nodules, abscesses, draining sinus tracts, and scarring with a prof...
Read MoreTrends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016
March 2023 | Volume 22 | Issue 3 | Original Article | 265 | Copyright © March 2023
Background: Antibiotic resistance related to prolonged antibiotic use is an emerging threat to public health. Objective: To evaluate recent trends in oral antibiotic use for acne trea...
Read MoreEfficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris
February 2023 | Volume 22 | Issue 2 | Original Article | 174 | Copyright © February 2023
Background: Two randomized phase 3 studies evaluated efficacy and safety of 1% clascoterone cream, a topical androgen receptor inhibitor, in patients aged ≥9 years with modera...
Read MoreBotulinum Toxin in the Oily Skin: Advantage of a Multi-Needle Device for a Controlled Release
January 2023 | Volume 22 | Issue 1 | Original Article | 41 | Copyright © January 2023
Background: Oily skin is one of the most common dermatological complaints. With the obligation to use masks to protect themselves from the Covid-19 virus, the problem has become even ...
Read MoreSUPPLEMENT INDIVIDUAL ARTICLES: Update on Truncal Acne: A Review of Treatments for a Neglected Disease and the Re-Emergence of Tazarotene
December 2022 | Volume 21 | Issue 12 | Supplement Individual Articles | SF3446185 | Copyright © December 2022
Acne vulgaris of the trunk carries with it a major psychosocial impact and an unmet need for adequate management. Approximately 50% of patients with facial acne also exhibit involvement of the back, c...
Read MoreSupplement Individual Article: Racial Ethnic Variations in Acne: A Practical Algorithm for Treatment and Maintenance, Including Skincare Recommendations for Skin of Color Patients With Acne
November 2022 | Volume 21 | Issue 11 | Supplement Individual Articles | SF3446083 | Copyright © November 2022
Background: Racial/ethnic differences in the clinical presentation, sequelae, and desired treatment outcomes for acne have been reported. Post-inflammatory hyperpigmentation (PIH) frequently occurs in...
Read MoreAdvances in Pigmentation Management: A Multipronged Approach
November 2022 | Volume 21 | Issue 11 | Original Article | 1206 | Copyright © November 2022
Background: Key cellular players regulating human skin pigmentation include melanocytes in the epidermis that synthesize melanin, neighboring keratinocytes that receive and distribute...
Read MoreMedia and other results for: "oral contraceptive"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
